The higher dose of interferon-beta-1a (Rebif; 44 mcg) appears to effective in patients with clinically isolated syndrome (CIS) suggestive of MS, according to the results of the phase III REFLEX trial (Comi et al. Lancet Neurol 2012;11:33-41).
Latest News
Treatment of motor symptoms of PD: MDS recommendations
April 11, 2012The Movement Disorder Society has presented new recommendations on the treatment of motor symptoms of Parkinson’s disease (Fox et al. Mov Disord 2011;26:S2-S41). The evidence-based review updates recommendations published in 2002 and 2004 (Goetz et al. Mov Disord 2002;17[suppl 4]:S1-S166; Goetz et al. Mov Disord 2005;20:523-539).
Inhaled ergotamine for migraine: phase III results
April 11, 2012MAP0004, a novel inhaled dihydroergotamine, is effective in the acute management of migraine, according to the results of the phase III FREEDOM-301 study (Aurora et al. Headache 2011; 51:507-517).
What is a relevant change in ADAS-cog?
April 11, 2012A 3-point change in the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-cog) score appears to be the minimal clinically relevant change for patients with mild Alzheimer’s disease (Schrag et al. J Neurol Neurosurg Psychiatry 2012;83:171-173).